Germany-based sample and assay technologies provider Qiagen has partnered with ID Solutions to enhance its digital PCR (dPCR) oncology research offerings.
The collaboration aims to strengthen Qiagen’s position in the field by leveraging ID Solutions’ expertise in assay development and manufacturing.
Under the terms of the agreement, ID Solutions will manufacture and supply dPCR assays for Qiagen’s QIAcuity platforms, specifically for non-clinical research.
The assays are designed to detect multiple mutations in both cell-free DNA from plasma and genomic DNA from formalin-fixed, paraffin-embedded tissue.
Qiagen will initially commercialise the kits in Europe, with plans to expand to other regions.
Qiagen vice president and Europe, Middle East and Africa (EMEA) region commercial operations head Simona Grandits said: “Through our collaboration with ID Solutions, we are reinforcing our commitment at Qiagen to providing comprehensive dPCR solutions on QIAcuity that address critical needs in oncology research.
“This agreement expands our assay portfolio, strengthens our position in oncology research, and supports faster, more reproducible results on the QIAcuity platform for our customers.”
The partnership supports Qiagen’s strategic goal of accelerating the adoption of its QIAcuity dPCR platform in oncology research.
The new assays will complement the company’s existing PanCancer Kits and over 200 LNA Mutation Assays available through its GeneGlobe platform.
GeneGlobe integrates pre-designed assays with a database of more than 10,000 biological entities, including genes and miRNAs.
For customers, the collaboration provides streamlined access to ready-to-use assays optimised for QIAcuity in non-clinical oncology research.
The enhanced offerings promise quicker results, often within a day, and cater to the growing demand for deeper molecular insights in the field.
The partnership aligns with ID Solutions’ goal of developing assays for research use on fully integrated platforms, further strengthening the potential impact on oncology research.
ID Solutions CEO Lise Grewis said: “Partnering with Qiagen enables us to extend the reach of our high-quality dPCR assays to more laboratories. Together, we’re enabling faster adoption of dPCR in oncology research with robust, reliable results.”
